Uncategorized

Australian medical diagnostics company Sonic Healthcare (ASX:SHL) has announced its acquisition of Swiss laboratory network Synlab Suisse for CHF100m ($250.9m). This strategic move marks a significant expansion of Sonic’s presence in Switzerland. The decision to purchase Synlab Suisse was prompted by Synlab Group, the parent company, divesting its Swiss operations, which currently employ 600 staff […]

Shares in KFC chain Collins Foods (ASX:CKF) surged on Tuesday following an impressive start to the 2023-24 financial year, despite concerns over rising inflation costs. While analysts expressed satisfaction with the results, CEO Drew O’Malley highlighted the delayed effect of inflation, which is expected to put pressure on margins throughout the coming year. Collins Foods

Moody’s Ratings has expressed strong approval for Northern Star’s (ASX:NST) $1.5 billion expansion plan for the SuperPit gold mine near Kalgoorlie. The company announced its intention to double production by 2029, aiming to increase output from the current 13 million tonnes to 27 million tonnes per year. The expansion is projected to nearly double gold

Bega Group (ASX: BGA), Australia’s largest locally owned food group, has issued a warning stating that escalating dairy prices could result in a substantial non-cash impairment of up to $180 million. This impairment is expected to push the company into a statutory loss for the year ending on June 30. In an announcement made to

BHP Group (ASX:BHP) CEO Mike Henry cautions against excessive government intervention in global critical minerals supply chains, emphasising the importance of international cooperation and competition to effectively accelerate the energy transition and combat climate change. At noon, the S&P/ASX 200 is 0.59 per cent higher at 7,120.70. The SPI futures are pointing to a rise

INOVIQ (ASX:IIQ) has announced excellent results from an independent clinical validation study of the company’s SubB2M/CA15-3 test for breast cancer detection. CEO Dr Leearne Hinch said: “Our blood test detected all-stages of breast cancer with 81% sensitivity and 93% specificity, outperforming a leading CA15-3 test.” Shares are trading 19 per cent higher at 60 cents.

Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company’s lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial. Tim McGowen: Today we’re talking with Chimeric Therapeutics (ASX:CHM). Market cap of around $16m. We have with us the CEO and Managing Director, Jennifer Chow.